rabbit anti igf2bp2  (Proteintech)

Journal: Non-coding RNA Research

Article Title: CircSMAD4 shapes matrix-remodeling TAMs in lung adenocarcinoma

doi: 10.1016/j.ncrna.2026.03.003

Figure Lengend Snippet: circSMAD4 physically associates with IGF2BP2 in macrophages. (A) LC–MS/MS summary of proteins enriched by circSMAD4 RNA pull-down. (B) Western blot validation of IGF2BP2 in circSMAD4 sense (vs antisense) pull-down from TC-hMDMs. (C) IGF2BP2 RIP–qPCR showing circSMAD4 enrichment over IgG in TC-hMDMs. (D–E) catRAPID prediction and ViennaRNA RNAfold secondary-structure modeling indicating multiple candidate IGF2BP2-binding regions on circSMAD4. (F) Western blot of IGF2BP2 after pull-down with circSMAD4 fragments (1#–3#). (G) Schematic of IGF2BP2 domain architecture and the Flag-tagged truncation/deletion constructs used for mapping circSMAD4 interaction (designed based on catRAPID prediction and annotated RRM/KH domain boundaries). (H) Anti-Flag RIP–qPCR showing circSMAD4 enrichment precipitated by the indicated Flag-tagged IGF2BP2 truncation/deletion constructs (presented as % input and normalized to IgG). (I) Nuclear–cytoplasmic fractionation followed by RT–qPCR showing circSMAD4 distribution and the effect of IGF2BP2 knockdown on the nuclear-to-cytoplasmic ratio of circSMAD4 in TC-hMDMs. Fractionation quality was validated using nuclear/cytoplasmic marker transcripts/proteins. (J) Representative immunofluorescence/ISH images showing circSMAD4 signals and IGF2BP2 staining in macrophages (CD163) with nuclear counterstaining (DAPI). Scale bar, 50 μm. (K–N) qPCR and Western blot showing no reciprocal change in expression between circSMAD4 and IGF2BP2 upon knockdown/overexpression. ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.

Article Snippet: Primary antibodies included IGF2BP2 (ABclonal, Cat# A5189), COL4A1 (ABclonal, Cat# A25131), E-cadherin (Proteintech, Cat# 20874-1-AP), N-cadherin (ABclonal, Cat# A0433), Vimentin (Proteintech, Cat# 10366-1-AP), α-SMA/ACTA2 (ABclonal, Cat# A7248), and β-Actin (ABclonal, Cat# AC026).

Techniques: Liquid Chromatography with Mass Spectroscopy, Western Blot, Biomarker Discovery, Binding Assay, Construct, Fractionation, Quantitative RT-PCR, Knockdown, Marker, Immunofluorescence, Staining, Expressing, Over Expression

Journal: Non-coding RNA Research

Article Title: CircSMAD4 shapes matrix-remodeling TAMs in lung adenocarcinoma

doi: 10.1016/j.ncrna.2026.03.003

Figure Lengend Snippet: circSMAD4 facilitates IGF2BP2-dependent stabilization of m6A-marked transcripts. (A) Venn diagram intersecting ENCORI-predicted IGF2BP2 targets with DEGs from shIGF2BP2 versus shNC and shcircSMAD4 versus shNC mRNA-seq, identifying shared candidates. (B) MeRIP–qPCR showing m6A enrichment on COL4A1, SPI1, and ACTA2 candidate regions (CRDs) in shNC and shIGF2BP2 cells. (C) IGF2BP2-RIP–qPCR showing IGF2BP2 binding to COL4A1, SPI1, and ACTA2 CRDs in shNC + Vector, shcircSMAD4 + Vector, shNC + IGF2BP2, and shcircSMAD4 + IGF2BP2 groups. (D) Biotin-circSMAD4 pull-down followed by qPCR showing enrichment of COL4A1, SPI1, and ACTA2 CRDs in Vector + shNC, circSMAD4 + shNC, Vector + shIGF2BP2, and circSMAD4 + shIGF2BP2 groups. (E–G) Schematics of m6A-site mutations introduced into COL4A1, SPI1, and ACTA2 reporters. (H–J) Dual-luciferase assays for CRD reporters (WT and m6A-mutant) in Vector, circSMAD4, and IGF2BP2 groups. (K–M) MeRIP–qPCR for WT and m6A-mutant CRD reporters in Vector, circSMAD4, and IGF2BP2 groups. (N–P) mRNA decay assays of endogenous COL4A1, SPI1, and ACTA2 following circSMAD4 knockdown with Vector or IGF2BP2 overexpression. Half-life estimated by one-phase decay (Y0 = 1, Plateau = 0). (Q–S) mRNA decay assays of endogenous COL4A1, SPI1, and ACTA2 following circSMAD4 overexpression with shNC or shIGF2BP2. Half-life estimated by one-phase decay (Y0 = 1, Plateau = 0). ∗P < 0.05; ∗∗P < 0.01; ∗∗∗P < 0.001; ∗∗∗∗P < 0.0001; ns, not significant.

Article Snippet: Primary antibodies included IGF2BP2 (ABclonal, Cat# A5189), COL4A1 (ABclonal, Cat# A25131), E-cadherin (Proteintech, Cat# 20874-1-AP), N-cadherin (ABclonal, Cat# A0433), Vimentin (Proteintech, Cat# 10366-1-AP), α-SMA/ACTA2 (ABclonal, Cat# A7248), and β-Actin (ABclonal, Cat# AC026).

Techniques: Binding Assay, Plasmid Preparation, Luciferase, Mutagenesis, Knockdown, Over Expression

Journal: Non-coding RNA Research

Article Title: CircSMAD4 shapes matrix-remodeling TAMs in lung adenocarcinoma

doi: 10.1016/j.ncrna.2026.03.003

Figure Lengend Snippet: Proposed model: circSMAD4 drives matrix-remodeling TAM programs in LUAD. Schematic summary illustrating that circSMAD4 in tumor-associated macrophages promotes a matrix-remodeling, M2-like state through two post-transcriptional routes: (i) circSMAD4 sequesters miR-562 in an AGO2-dependent manner to relieve repression of COL4A1 mRNA; (ii) circSMAD4 associates with IGF2BP2 to enhance the stability of m6A-marked transcripts, including COL4A1, SPI1, and ACTA2 (α-SMA). These combined outputs reinforce extracellular matrix remodeling within the LUAD tumor microenvironment.

Article Snippet: Primary antibodies included IGF2BP2 (ABclonal, Cat# A5189), COL4A1 (ABclonal, Cat# A25131), E-cadherin (Proteintech, Cat# 20874-1-AP), N-cadherin (ABclonal, Cat# A0433), Vimentin (Proteintech, Cat# 10366-1-AP), α-SMA/ACTA2 (ABclonal, Cat# A7248), and β-Actin (ABclonal, Cat# AC026).

Techniques:

Journal: Non-coding RNA Research

Article Title: The regulatory role of circGDI2 in hepatocellular carcinoma proliferation and glycolysis with the involvement of m6A modification

doi: 10.1016/j.ncrna.2025.11.006

Figure Lengend Snippet: Silencing circGDI2 inhibits proliferation and glycolysis and PKM2 expression through IGF2BP2 in HCC cells. (A) Western blot was used to analyze IGF2BP2 expression in Li-7 and Huh-7 cell lines after circGDI2 knockdown. (B) The expression level of IGF2BP2 was examined in clinical HCC tissues and adjacent normal tissues using RT-qPCR. To clarify if circGDI2 regulated HCC cell proliferation and glycolysis through IGF2BP2, sh-circGDI2 and OE-IGF2BP2 were co-transfected into Li-7 and Huh-7 cells. (C) Western blot was used to assess the effect of IGF2BP2 on the expression of PKM2. (D) CCK-8 assay was used to assess cell proliferation. (E) Glucose consumption level and lactate production were detected using the Glucose Assay Kit with O-toluidine and Lactate Assay Kit. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, vs. the sh-NC group, or the Adjacent group. # P < 0.05, ## P < 0.01, ### P < 0.001, vs. the sh-circGDI2+OE-NC group.

Article Snippet: IGF2BP2 , IHC , Rabbit , 1:500 , Proteintech , 11601-1-AP.

Techniques: Expressing, Western Blot, Knockdown, Quantitative RT-PCR, Transfection, CCK-8 Assay, Glucose Assay, Lactate Assay

Journal: Non-coding RNA Research

Article Title: The regulatory role of circGDI2 in hepatocellular carcinoma proliferation and glycolysis with the involvement of m6A modification

doi: 10.1016/j.ncrna.2025.11.006

Figure Lengend Snippet: Silencing circGDI2 inhibits HCC tumor growth and PKM2 expression through IGF2BP2. To verify the effect of circGDI2 and IGF2BP2 on HCC tumor growth, a xenograft mouse model was constructed. (A) Pictures of the isolated tumors of the indicated group. (B) The tumor volume and weight were recorded. (C) HE staining, Tunel and Ki-67 staining were performed to observe the histological characteristics and cell proliferation in the tumor tissues (scale bar = 100 μm). (D) RT-qPCR was used to detect circGDI2, IGF2BP2 and PKM2 levels. (E) IHC was used to detect IGF2BP2 and PKM2 levels (scale bar = 100 μm). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, vs. the sh-NC group. # P < 0.05, ## P < 0.01, ### P < 0.001, vs. the sh-circGDI2+OE-NC group.

Article Snippet: IGF2BP2 , IHC , Rabbit , 1:500 , Proteintech , 11601-1-AP.

Techniques: Expressing, Construct, Isolation, Staining, TUNEL Assay, Quantitative RT-PCR

Journal: Non-coding RNA Research

Article Title: The regulatory role of circGDI2 in hepatocellular carcinoma proliferation and glycolysis with the involvement of m6A modification

doi: 10.1016/j.ncrna.2025.11.006

Figure Lengend Snippet: Silencing FTO inhibits HCC tumor growth and decreases circRNA, IGF2BP2 and PKM2 levels. To investigate the biological role of FTO on HCC tumor growth, the xenograft tumor models of HCC cells in the sh-NC and sh-FTO groups were established. (A) Pictures of the isolated tumors of the indicated group. (B) The tumor volume and weight were recorded. (C) HE staining, Ki-67 staining and Tunel stainning were performed to observe the histological characteristics and cell proliferation in the tumor tissues (scale bar = 100 μm). (D) RT-qPCR was used to detect circGDI2 and FTO levels. (E) IHC was used to detect IGF2BP2 and PKM2 levels (scale bar = 100 μm). ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001, vs. the sh-NC group.

Article Snippet: IGF2BP2 , IHC , Rabbit , 1:500 , Proteintech , 11601-1-AP.

Techniques: Isolation, Staining, TUNEL Assay, Quantitative RT-PCR

Journal: Discover Oncology

Article Title: Novel N 6 -methyladenosine (m 6 A) writer METTL16 promotes the cervical cancer tumorigenesis by targeting FTH1-dependent ferroptosis

doi: 10.1007/s12672-026-04403-8

Figure Lengend Snippet: FTH1 acted as the target of METTL16. A The immunofluorescence assay showed the subcellular localization of METTL16 and FTH1. B The binding motif sites of METTL16 for its target genes (GGAAC). C The FTH1 level in cervical cancer cells was test by the RT-PCR. D RNA immunoprecipitation (RIP) assay was conducted for the binding within METTL16 and FTH1 in HeLa cells. E RIP assay using anti-m 6 A conducted for the m 6 A modification on FTH1 mRNA. * p < 0.05, ** p < 0.01

Article Snippet: Cervical cancer cells were lysed by immunoprecipitation buffer (protease, phosphatase inhibitors, MCE) containing magnetic beads conjugated to specific antibodies (anti-IGF2BP2, anti-METTL16, anti-m 6 A).

Techniques: Immunofluorescence, Binding Assay, Reverse Transcription Polymerase Chain Reaction, RNA Immunoprecipitation, Modification

Journal: Discover Oncology

Article Title: Novel N 6 -methyladenosine (m 6 A) writer METTL16 promotes the cervical cancer tumorigenesis by targeting FTH1-dependent ferroptosis

doi: 10.1007/s12672-026-04403-8

Figure Lengend Snippet: IGF2BP2 promoted the stability of FTH1 mRNA. A The immunofluorescent staining showed the subcellular localization of IGF2BP2 and FTH1 in HeLa cells. B The positive correlation within IGF2BP2 and FTH1 in clinical samples ( http://gepia.cancer-pku.cn/index.html ). C RNA immunoprecipitation (RIP) assay showed the immunoprecipitated FTH1 mRNA by anti-IGF2BP2 antibody. D RNA decay analysis reported the stability of FTH1 mRNA in cervical cancer cells with IGF2BP2 overexpression. E RNA decay analysis reported the stability of FTH1 mRNA in cervical cancer cells with METTL16 silencing (sh-METTL16-1, sh-METTL16-2). F RNA decay analysis reported the stability of FTH1 mRNA in cervical cancer cells with IGF2BP2 silencing (si-IGF2BP2) and METTL16 overexpression. * p < 0.05, ** p < 0.01

Article Snippet: Cervical cancer cells were lysed by immunoprecipitation buffer (protease, phosphatase inhibitors, MCE) containing magnetic beads conjugated to specific antibodies (anti-IGF2BP2, anti-METTL16, anti-m 6 A).

Techniques: Staining, RNA Immunoprecipitation, Immunoprecipitation, Over Expression